Outcome

This study highlights the potential of Hyperbaric Oxygen Therapy (HBOT) as a complementary treatment approach for HIV infection. Conducted in vitro with Peripheral Blood Mononuclear Cells (PBMCs) from healthy volunteers the study demonstrated that HBOT at 2.4 ATA with 100% oxygen induced significant cellular responses that suppress HIV replication.

Introduction

Hyperbaric oxygen therapy (HBOT) at a pressure of 2.4 ATA and 100% oxygen has demonstrated significant potential in suppressing HIV-1 replication. This study delves into the mechanisms by which HBOT affects HIV-1 in Peripheral Blood Mononuclear Cells (PBMCs) cultured from healthy volunteers. The findings reveal that HBOT notably enhances the expression of the transcription factor NFκB the reverse transcriptase inhibitor p21 protein and mRNA transcription of interferon α2 leading to a marked decrease in HIV-1 p24 antigen levels. Consequently HBOT appears to induce cellular adaptive responses that inhibit HIV replication suggesting that HBOT may offer a novel and complementary approach for managing chronic HIV infection. This research underscores the significance of further exploring the innovative potential of HBOT in the treatment of viral diseases.

Results

The study assessed the impact of Hyperbaric Oxygen Therapy (HBOT) on HIV-1 replication in Peripheral Blood Mononuclear Cells (PBMCs) from healthy volunteers. Utilizing a controlled in vitro environment PBMCs were exposed to 2.4 ATA and 100% oxygen across five sessions each comprising three 30-minute exposures with 5-minute intervals.

Key findings revealed notable changes in cellular behavior and HIV-1 activity due to HBOT:

1. Increased Expression of NFκB: HBOT significantly raised the levels of transcription factor NFκB in the treated PBMCs. This factor is critical for initiating immune responses suggesting an enhanced cellular ability to combat viral replication.
2. Elevation in p21 Protein: The concentration of p21 a reverse transcriptase inhibitor also increased significantly. p21 aids in halting the replication of HIV-1 indicating that HBOT may contribute to hindering the virus’s lifecycle.
3. Enhanced mRNA Transcription of Interferon α2: HBOT treatment led to a substantial rise in the mRNA transcription levels of interferon α2 an important antiviral molecule. This suggests that HBOT aids in priming immune cells to mount a more effective antiviral response.
4. Reduction in HIV-1 p24 Antigen: There was a marked decrease in HIV-1 p24 antigen levels in cells treated with HBOT. The p24 antigen is a core protein of the virus and its reduction is indicative of suppressed viral replication.

Interestingly no significant difference was observed in the protein concentration of interferon α between the treated and control groups. This points to a specific modulation at the genetic transcription level rather than at the protein expression level within the parameters of this study.

The results suggest that HBOT triggers cellular adaptive responses through mechanisms likely involving reactive oxygen and nitrogen species (ROS and RNS). These reactive species enhance the expression of antiviral factors like NFκB and p21 leading to the suppression of HIV-1 replication. This highlights HBOT’s potential as a supplementary treatment in managing HIV infection by bolstering host immune defenses and inhibiting virus proliferation.

In summary this study demonstrates that HBOT can effectively augment significant immune responses and suppress HIV-1 replication in vitro offering a promising complementary approach to existing HIV treatments.

Conclusion

In conclusion our study highlights the promising potential of Hyperbaric Oxygen Therapy (HBOT) as a complementary approach in managing HIV infection. The in vitro experiment demonstrated that HBOT at 2.4 ATA with 100% oxygen significantly enhances the expression of transcription factor NFκB the reverse transcriptase inhibitor p21 protein and the mRNA transcription of interferon α2 in Peripheral Blood Mononuclear Cells (PBMCs). This cellular response was accompanied by a marked reduction in HIV-1 p24 antigen levels indicating effective suppression of viral replication.

These findings suggest that HBOT can trigger crucial immune responses likely through the induction of reactive oxygen and nitrogen species thereby promoting antiviral mechanisms that inhibit HIV replication. The enhanced expression of NFκB p21 and interferon α2 mRNA underscores the therapy’s potential to fortify the body’s defense against HIV.

While the results provide a robust foundation they are derived from an in vitro model. Consequently further research involving clinical trials is imperative to validate the efficacy and safety of HBOT in HIV patients. This study paves the way for future exploration into HBOT as an innovative therapeutic avenue potentially offering a new dimension in the treatment landscape for HIV and other chronic viral infections.